Crucell Biotechs

Crucell is a biotechnology company specializing in the development, production, and commercialization of vaccines and antibodies to prevent and treat infectious diseases. The company is best known for its proprietary PER.C6 human cell line technology, which provides a high-yield, scalable platform for the manufacturing of biological products including viral vaccines and monoclonal antibodies. Crucell's portfolio historically included marketed vaccines for pediatric diseases, hepatitis, and travel-related illnesses like cholera and typhoid. In 2011, the company was acquired by Johnson & Johnson for approximately $2.4 billion and was subsequently integrated into the Janssen Pharmaceutical Companies. Today, its legacy and technologies continue through Janssen Vaccines, focusing on global health threats including Ebola, HIV, and RSV.